Effects of TNF-α-308G/A Polymorphism on the Risk of Diabetic Nephropathy and Diabetic Retinopathy: An Updated Meta-Analysis

Abstract

Diabetic nephropathy (DN) and diabetic retinopathy (DR) are the major factors of morbidity and mortality in the patients with diabetes mellitus (DM). Growing studies have investigated the relationship between the TNF-α-308G/A polymorphism and the susceptibility to DN and DR, without achieving consensus. Thus, we conducted this meta-analysis to reach more comprehensive conclusions for these issues. Eligible studies were retrieved through electronic databases such as PubMed, Embase, Web of Science and China National Knowledge Infrastructure. Summary of odds ratios (OR) and 95% confidence intervals (CIs) were generated to evaluate the intensity of the associations. Statistical analyses were performed by STATA 11.0 and RevMan 5.2. There are fourteen eligible publications involving nineteen studies in this meta-analysis. TNF-α-308G/A polymorphism was significantly related to increasing risk of DN under recessive model (OR=1.37, 95% CI=1.03–1.83) and homozygous model (OR=1.54, 95% CI=1.15–2.06). Moreover, the similar results were also obtained in Asian groups for DN (recessive: OR=1.69, 95% CI=1.18–2.42; homozygous: OR=1.99, 95% CI=1.38–2.86; respectively), and significant association was also detected between TNF-α-308G/A and DN susceptibility in type 2 DM in recessive model (OR=1.39, 95% CI=1.02–1.89). No significant association was observed between TNF-α-308G/A and DR susceptibility in total analyses and subgroup analyses by ethnicity and type of DM. TNF-α-308G/A polymorphism may enhance the susceptibility to diabetic nephropathy, especially in Asian population and in T2DM patients, but not diabetic retinopathy.

Key words

TNF-a-308G/A - polymorphism - meta-analysis - diabetic nephropathy - diabetic retinopathy - genetic models

Publication History

Received: 28 November 2019

Accepted after revision: 09 April 2020

Article published online:
05 May 2020

• References

• 1 Jamil K, Jayaraman A, Ahmad J. et al. TNF-alpha-308G/A and -238G/A polymorphisms and its protein network associated with type 2 diabetes mellitus. Saudi J Biol Sci 2017; 24: 1195-1203
• 2 Wei L, Xiao Y, Li L. et al. The susceptibility genes in diabetic nephropathy. Kidney Dis (Basel, Switzerland) 2018; 4: 226-237
• 3 Kaul K, Hodgkinson A, Tarr JM. et al. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?. Curr Diabetes Rev 2010; 6: 294-303
• 4 Tesch GH. Diabetic nephropathy – Is this an immune disorder?. Clin Sci (London, England: 1979) 2017; 131: 2183-2199
• 5 Persson F, Rossing P. Diagnosis of diabetic kidney disease: State of the art and future perspective. Kidney Int Suppl 2018; 8: 2-7
• 6 Heng LZ, Comyn O, Peto T. et al. Diabetic retinopathy: Pathogenesis, clinical grading, management and future developments. Diabetic Med 2013; 30: 640-650
• 7 Kempen JH, O'Colmain BJ, Leske MC. et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (Chicago, Ill: 1960) 2004; 122: 552-563
• 8 Davoudi S, Sobrin L. Novel genetic actors of diabetes-associated microvascular complications: Retinopathy, kidney disease and neuropathy. Rev Diabetic Stud 2015; 12: 243-259
• 9 Skrunes R, Svarstad E, Reisaeter AV. et al. Familial clustering of ESRD in the Norwegian population. Clin J Am Soc Nephrol 2014; 9: 1692-1700
• 10 Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars Immunopathol 2008; 30: 65-84
• 11 Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retinal Eye Res 2011; 30: 343-358
• 12 Dabhi B, Mistry KN. Oxidative stress and its association with TNF-alpha-308 G/C and IL-1alpha-889 C/T gene polymorphisms in patients with diabetes and diabetic nephropathy. Gene 2015; 562: 197-202
• 13 Lampropoulou IT, Stangou M, Papagianni A. et al. TNF-α and microalbuminuria in patients with type 2 diabetes mellitus. J Diabetes Res 2014; 2014: 394206
• 14 Skoog T, van't Hooft FM, Kallin B. et al. A common functional polymorphism (C-->A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-α) gene associated with reduced circulating levels of TNF-α. Hum Mol Genet 1999; 8: 1443-1449
• 15 Vendrell J, Fernandez-Real JM, Gutierrez C. et al. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003; 167: 257-264
• 16 Chang WT, Wang YC, Chen CC. et al. The -308G/A of Tumor Necrosis Factor (TNF)-alpha and 825C/T of Guanidine Nucleotide Binding Protein 3 (GNB3) are associated with the onset of acute myocardial infarction and obesity in Taiwan. Int J Mol Sci 2012; 13: 1846-1857
• 17 Yeo ES, Hwang JY, Park JE. et al. Tumor necrosis factor (TNF-alpha) and C-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. Yonsei Med J 2010; 51: 519-525
• 18 Jamil K, Haq O, Ahmed Z, Joshi S. Polymorphism of TNF-α as a biomarker of diabetic nephropathy in patients of Telangana Region. Madridge J Case Rep Stud 2019; 4: 158-162
• 19 Li X, Wu TT, Chen J. et al. Elevated expression levels of serum insulin-like growth factor-1, tumor necrosis factor-alpha and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy. J Diabetes Invest 2017; 8: 108-114
• 20 Babel N, Gabdrakhmanova L, Hammer MH. et al. Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease. J Nephrol 2006; 19: 802-807
• 21 Yoshioka K, Yoshida T, Takakura Y. et al. Relationship between polymorphisms 804C/A and 252A/G of lymphotoxin-alpha gene and -308G/A of tumor necrosis factor alpha gene and diabetic retinopathy in Japanese patients with type 2 diabetes mellitus. Metabolism Clin Exp 2006; 55: 1406-1410
• 22 Wang N, Huang K, Zou H. et al. No association found between the promoter variants of TNF-α and diabetic retinopathy in Chinese patients with type 2 diabetes. Curr Eye Res 2008; 33: 377-383
• 23 Hameed I, Masoodi SR, Malik PA. et al. Genetic variations in key inflammatory cytokines exacerbates the risk of diabetic nephropathy by influencing the gene expression. Gene 2018; 661: 51-59
• 24 Kung WJ, Lin CC, Liu SH. et al. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technol Therap 2010; 12: 809-813
• 25 Lee SH, Lee TW, Ihm CG. et al. Genetics of diabetic nephropathy in type 2 DM: Candidate gene analysis for the pathogenic role of inflammation. Nephrology (Carlton, Vic) 2005; 10: S32-S36
• 26 Lindholm E, Bakhtadze E, Cilio C. et al. Association between LTA, TNF and AGER polymorphisms and late diabetic complications. PLoS One 2008; 3: e2546
• 27 Prasad P, Tiwari AK, Kumar KM. et al. Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet 2007; 8: 20
• 28 Rodrigues KF, Pietrani NT, Sandrim VC. et al. Association of a large panel of cytokine gene polymorphisms with complications and comorbidities in type 2 diabetes patients. J Diabetes Res 2015; 2015: 605965-.
• 29 Sikka R, Raina P, Matharoo K. et al. TNF-alpha (g.-308 G>A) and ADIPOQ (g.+45 T>G) gene polymorphisms in type 2 diabetes and microvascular complications in the region of Punjab (North-West India). Curr Eye Res 2014; 39: 1042-1051
• 30 Umapathy D, Krishnamoorthy E, Mariappanadar V. et al. Increased levels of circulating (TNF-alpha) is associated with (-308G/A) promoter polymorphism of TNF-alpha gene in Diabetic Nephropathy. Int J Biol Macromol 2018; 107: 2113-2121
• 31 Paine SK, Sen A, Choudhuri S. et al. Association of tumor necrosis factor alpha, interleukin 6, and interleukin 10 promoter polymorphism with proliferative diabetic retinopathy in type 2 diabetic subjects. Retina (Philadelphia, Pa) 2012; 32: 1197-1203
• 32 Sesti LF, Crispim D, Canani LH. et al. The -308G>a polymorphism of the TNF gene is associated with proliferative diabetic retinopathy in Caucasian Brazilians with type 2 diabetes. Invest Ophthalmol Vis Sci 2015; 56: 1184-1190
• 33 Fathy SA, Mohamed MR, Ali MAM. et al. Influence of IL-6, IL-10, IFN-gamma and TNF-alpha genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers 2019; 24: 43-55
• 34 Nicholson G, Hall GM. Diabetes mellitus: New drugs for a new epidemic. Br J Anaest 2011; 107: 65-73
• 35 Tahrani AA, Bailey CJ, Del Prato S. et al. Management of type 2 diabetes: New and future developments in treatment. Lancet (London, England) 2011; 378: 182-197
• 36 Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: Review of the epidemiological evidence. Cancer Sci 2013; 104: 9-14
• 37 Han SB, Yang HK, Hyon JY. Influence of diabetes mellitus on anterior segment of the eye. Clin Intervent. Aging 2019; 14: 53-63
• 38 Browning DJ, Stewart MW, Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol 2018; 66: 1736-1750
• 39 Zhu W, Wu Y, Meng YF. et al. Association of obesity and risk of diabetic retinopathy in diabetes patients: A meta-analysis of prospective cohort studies. Medicine 2018; 97: e11807
• 40 Zoungas S, Arima H, Gerstein HC. et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5: 431-437
• 41 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England) 1998; 352: 837-853
• 42 Cannon A, Handelsman Y, Heile M. et al. Burden of illness in type 2 diabetes mellitus. J Managed Care Special Pharm 2018; 24: S5-S13
• 43 Stehouwer CDA Microvascular dysfunction and hyperglycemia: A vicious cycle with widespread consequences. Diabetes 2018; 67: 1729-1741
• 44 Agrawal NK, Kant S. Targeting inflammation in diabetes: Newer therapeutic options. World J Diabetes 2014; 5: 697-710
• 45 Assar ME, Angulo J, Rodriguez-Manas L. Diabetes and ageing-induced vascular inflammation. J Physiol 2016; 594: 2125-2146
• 46 Bianchi E, Ripandelli G, Taurone S. et al. Age and diabetes related changes of the retinal capillaries: An ultrastructural and immunohistochemical study. Int J Immunopathol Pharmacol 2016; 29: 40-53
• 47 Li H, Groop L, Nilsson A. et al. A combination of human leukocyte antigen DQB1*02 and the tumor necrosis factor alpha promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2767-2774
• 48 Nishimura M, Obayashi H, Mizuta I. et al. TNF, TNF receptor type 1, and allograft inflammatory factor-1 gene polymorphisms in Japanese patients with type 1 diabetes. Hum Immunol 2003; 64: 302-309
• 49 Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55: 1139-1149
• 50 Peng Y, Li LJ. TNF-alpha-308G/A polymorphism associated with TNF-α protein expression in patients with diabetic nephropathy. Int J Clin Exp Pathol 2015; 8: 3127-3131
• 51 Thomaidou S, Zaldumbide A, Roep BO. Islet stress, degradation and autoimmunity. Diabetes Obes Metab 2018; 20 (Suppl 2): 88-94
• 52 Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-399
• 53 Vaux DL, Flavell RA. Apoptosis genes and autoimmunity. Curr Opin Immunol 2000; 12: 719-724
• 54 Liu LS, Spelleken M, Rohrig K. et al. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: Implication of the p80 tumor necrosis factor receptor. Diabetes 1998; 47: 515-522
• 55 Aguirre V, Uchida T, Yenush L. et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-9054
• 56 Zhao Y, Yang J, Zhang L. et al. Association between TNF-alpha -308G/A polymorphism and diabetic nephropathy risk: A meta-analysis. Int Urol Nephrol 2013; 45: 1653-1659
• 57 Meng N, Zhang Y, Li H. et al. Association of tumor necrosis factor alpha promoter polymorphism (TNF-alpha 238 G/A and TNF-alpha 308 G/A) with diabetic mellitus, diabetic retinopathy and diabetic nephropathy: A meta-analysis. Curr Eye Res 2014; 39: 194-203